| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q2 2016 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SERES THERAPEUTICS INC | 29 | Q3 2023 | 68.0% |
| DENALI THERAPEUTICS INC | 24 | Q3 2023 | 50.9% |
| SYROS PHARMACEUTICALS INC | 24 | Q2 2022 | 27.3% |
| MODERNA INC | 20 | Q3 2023 | 76.9% |
| EVELO BIOSCIENCES INC | 20 | Q1 2023 | 41.2% |
| RUBIUS THERAPEUTICS INC | 18 | Q4 2022 | 60.7% |
| Axcella Health Inc | 17 | Q2 2023 | 3.5% |
| KALEIDO BIOSCIENCES INC | 13 | Q1 2022 | 9.5% |
| Foghorn Therapeutics Inc | 12 | Q3 2023 | 6.5% |
| Sana Biotechnology Inc | 11 | Q3 2023 | 18.4% |
View Flagship Pioneering Inc.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-15 |
| 4 | 2023-08-15 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-07-13 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-02-27 |
| 13F-HR | 2023-02-14 |
View Flagship Pioneering Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.